Gaucher disease is a rare inherited metabolic disorder caused by reduced activity of an enzyme called glucocerebrosidase. This causes fatty substances, particularly glucosylceramide, to accumulate inside certain cells and can affect the spleen, liver, bone marrow, and bones. Some forms can also affect the nervous system. Treatment depends on the type of Gaucher disease, symptoms, age, organ involvement, and overall health. For many people with type 1 Gaucher disease, disease-specific treatment can substantially improve blood abnormalities, organ enlargement, and some bone complications.
Gaucher disease is commonly divided into three clinical types.
Type 1 is the most common form. It primarily affects the blood, spleen, liver, and bones and usually does not cause significant primary neurological disease.
Type 2 is an acute neuronopathic form that can cause severe neurological problems during infancy or early childhood.
Type 3 is a chronic neuronopathic form. It can cause the same systemic complications seen in type 1 along with progressive neurological manifestations.
The treatment approach differs among these forms because therapies that improve the systemic effects of Gaucher disease may not correct neurological damage.
Treatment generally aims to:
Treatment is usually coordinated by specialists familiar with rare metabolic disorders.
Enzyme replacement therapy (ERT) is a major disease-specific treatment for Gaucher disease, particularly type 1.
ERT provides a manufactured form of the deficient enzyme. The replacement enzyme helps the body break down accumulated glucosylceramide.
Examples of recombinant enzyme preparations include:
These medicines are administered intravenously. Treatment schedules and doses are individualized according to disease severity and response.
ERT can improve blood abnormalities and reduce liver and spleen enlargement. Long-term treatment can also improve bone-related outcomes in many people with type 1 disease.
Substrate reduction therapy (SRT) works differently from ERT.
Instead of replacing the missing enzyme, SRT reduces production of the substance that accumulates in Gaucher disease. This reduces the amount of material that needs to be broken down by the body's residual enzyme activity.
Oral SRT medicines include:
These medications are intended for selected patients, and eligibility can depend on factors such as age, disease type, kidney function, genetic characteristics, drug interactions, and treatment history.
The two major disease-specific approaches work through different mechanisms.
| Treatment | How It Works | Administration |
|---|---|---|
| Enzyme replacement therapy | Replaces deficient glucocerebrosidase activity | Intravenous infusion |
| Substrate reduction therapy | Reduces production of accumulated substrate | Oral medication |
The choice between therapies should be made with a Gaucher disease specialist based on the individual's disease characteristics and treatment needs.
Gaucher disease can cause anemia because abnormal cells accumulate in the bone marrow and spleen.
Disease-specific treatment can improve anemia over time. In cases of severe anemia, blood transfusions may be necessary as supportive treatment.
Persistent anemia despite appropriate treatment may require evaluation for another contributing condition.
Low platelet counts can increase the risk of bruising and bleeding.
Treating the underlying Gaucher disease can improve platelet counts in many affected individuals. Severe bleeding may require blood-product support.
People with significant thrombocytopenia may need specialist guidance before surgery or invasive dental procedures.
Gaucher cells can accumulate in the spleen and liver, causing enlargement.
ERT and SRT can reduce organ enlargement in appropriate patients.
Splenectomy, or surgical removal of the spleen, is generally avoided when effective disease-specific therapy is available because removing the spleen can increase the risk of certain long-term bone complications. It may still be considered in unusual circumstances involving severe splenic disease or persistent dangerous thrombocytopenia.
Bone involvement is an important complication of Gaucher disease.
Possible manifestations include:
Disease-specific therapy can reduce some bone complications, but established structural damage may not be reversible.
Additional management may include:
Bone crises can cause episodes of severe pain and inflammation.
Treatment may include pain management, rest during acute episodes, hydration when appropriate, and specialist evaluation.
Repeated or severe bone symptoms may require imaging such as MRI to evaluate bone damage.
Neurological involvement is most characteristic of types 2 and 3 Gaucher disease.
Possible neurological manifestations include:
ERT can improve many systemic manifestations but does not adequately reach the brain to reverse severe neurological disease.
Neurological symptoms therefore require evaluation and supportive treatment from appropriate specialists.
Type 2 Gaucher disease is associated with severe early neurological disease.
Current disease-specific therapies do not reliably alter the severe neurological manifestations of type 2 disease. GeneReviews notes that individuals with type 2 disease are not considered appropriate candidates for ERT, SRT, or hematopoietic stem-cell transplantation as therapies capable of changing the neurological course.
Care is therefore often focused on symptom management, nutrition, respiratory support, seizure management, swallowing safety, and family support.
Type 3 disease combines systemic Gaucher manifestations with chronic neurological involvement.
ERT can treat systemic complications, but neurological manifestations may continue to require specialized management.
Depending on symptoms, care may involve neurologists, physical therapists, speech and swallowing specialists, nutrition professionals, and other members of a multidisciplinary team.
Hematopoietic stem cell transplantation has historically been considered for selected severe cases, particularly some individuals with chronic neurological disease.
However, it is not a routine treatment for most people with Gaucher disease and carries significant risks. GeneReviews identifies it as a potential option in selected severe cases rather than standard therapy for everyone.
Regular monitoring helps determine whether treatment is working and whether complications are developing.
Monitoring may include:
Imaging can also be used to monitor disease progression and treatment response.
Gaucher disease is inherited in an autosomal recessive pattern.
Genetic testing can help confirm the diagnosis and identify the disease-causing variants in the GBA1 gene. Genetic counseling can help explain carrier status, inheritance patterns, and reproductive considerations.
Testing may also be appropriate for relatives of someone diagnosed with Gaucher disease.